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The effect of 5-fluorouracil (5-FU) pretreatment on human bone marrow (BM) progenitor/stem cells and recovery of hematopoiesis after autologous marrow transplant was studied. Twenty-one patients were treated with 5-FU (1 5 mg/kg to 45 mg/kg) intravenously (IV) for 1 to 3 days administered 6 to 22 days before BM harvest. Post-FU marrow was infused into 15 patients after high-dose cyclophosphamide, carmustine (BCNU), and VP-16 (CBV). Seventeen patients (historical controls) were treated with CBV and autologous BM transplantation but did not receive 5-FU before marrow harvest. The groups were comparable for diagnosis and prior therapy. In the 5-FU-treated group and control group, median recovery times for platelet count to 50,000/mm3 were 20 and 30 days, respectively (P = .007), and for platelet count to 1 O0,000/mm3, 23 and 38 days, respectively (P = .007), while neutrophil recovery was not significantly altered. In vitro cultures with 1 to 7 growth factors (interleukin-1 [IL-11, IL-3, IL-4, IL-6, colonystimulating factor-1 [CSF-I], granulocyte-macrophage colony-stimulating factor [GM-CSF], and G-CSF) were performed. In 8 of 10 patients whose marrow was studied
UTOLOGOUS BONE marrow transplantation (ABMT)
A permits the delivery of marrow ablative high-dose chemotherapy with or without total body irradiation to treat patients with recurrent lymphomas or leukemias.'.' After treatment and subsequent transplantation, a finite period of pancytopenia occurs before hematopoietic renewal. Based on limited animal and human studies, a minimal number of transplanted nucleated cells is required for proper engraftment, beyond which further increases in cell number do not improve the time to marrow recovery.' Shortening the time required for marrow recovery may improve survival and lessen morbidity.3-' Techniques to shorten recovery in humans have included the use of recombinant human hematopoietic growth factors (HGF) after transplantation of stem cells3-' or the use of chemotherapy mobilization ofperipheral blood (PB) stem cells with or without growth factors.6'"
In animal systems a number of other in vivo manipulations have led to improved marrow recovery after irradiation. These have included pretreatment with vinblastine or vincristine, endotoxin, or low-dose irradiation.''-" In addition, marrow from mice pretreated with 5-fluorouracil (5-FU) is enriched in putative primitive stem cells (high proliferative potential colony-forming cell, [HPP-CFC]) and is associated with rapid marrow recovery.I6-'* We have previously described the human equivalent of murine HPP-CFC. 19 These cells responded to granulocytemacrophage colony-stimulating factor (GM-CSF) plus interleukin-3 (IL-3), occur at very low frequency in normal marrow, and were enriched in marrow harvests after 5-FU treatment.
The present study evaluates the nature of the HPP-CFC occurring at varying times after 5-FU administration to patients in an autologous marrow transplant program and the hematopoietic recovery seen in patients transplanted with their "post-FU" marrow.
before and after 5-FU treatment, the numbers of CFU-C responsive to the combination of GM-CSF and IL-3 was increased 6.1 5-fold by 5-FU pretreatment. In 4 of these patients, thymidine suicide of GM-CSF-and IL-3-stimulated CFU-C ranged from 17% to 42%. High proliferative potential colony-forming cell (HPP-CFC) was observed in low frequency in normal marrow and patient's marrow before 5-FU treatment. In l l of 16 patients pretreated with 5-FU, increased numbers of HPP-CFC were noted. GM-CSF and IL-3 interacted synergistically to stimulate HPP-CFC.
Multifactor combinations, especially GM-CSF + G-CSF + IL-3 + IL-6 + IL-1 + CSF-1 did not increase total colony count or classic HPP-CFC but did result in altered morphology, producing huge, loose colonies. The marrow from patients pretreated with 5-FU is enriched with multifactorresponsive HPP-CFC, renews in vivo granulopoiesis in a manner comparable with marrow harvests without 5-FU pretreatment, and provides accelerated in vivo platelet recovery. This marrow may be an appropriate target marrow for gene insertion in gene-therapy protocols.
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MATERIALS AND METHODS
Patient characteristics and treatment. Thirty-two patients who had failed standard treatment for a variety of different neoplastic diseases were treated with high-dose CBV (cyclophosphamide, carmustine [BCNU] , and VP-16 [etoposide] ) followed by autologous marrow transplantation with either 5-FU-primed marrow (15 patients) or unmanipulated marrow ( I 7 patients). No patients treated with CBV at our institution were excluded from this analysis. The age of the patients ranged from 18 to 62. The majority of patients had Hodgkin's disease. Bone marrow (BM) criteria for undergoing transplantation included the absence of tumor involvement in the BM as determined by bilateral posterior iliac crest marrow aspirates and biopsies, normal PB counts, the presence of 30% or greater cellularity estimated from bilateral BM biopsies and no history of prior pelvic irradiation.
5-FU marrowpretreatment. Twenty-nine patients underwent pretreatment with 5-FU I5 mg/kg to 45 mg/kg [total dose] over I to 3 days) 6 to 22 days before marrow harvest as summarized in Table I . In vitro data were available for 22 patients. Fifteen patients pretreated with 5-FU underwent harvest and treatment with CBV followed by transplant. All were fully evaluable for Abbreviations: DX, diagnosis; CT/RT, chemotherapy/radiation therapy; Tx, treatment; NHL. non-Hodgkin's lymphoma; HD, Hodgkin's disease; Radiation therapy administered as at least one of the treatments.
ANC. absolute neutrophil count; TES, testicular cancer; Sarcom, sarcoma; Neuro, neuroblastoma; Sin cell, small cell cancer; Ovar, ovarian cancer. hematologic recovery. Five patients pretreated with 5-FU were conditioned with regimens other than CBV. The remaining nine patients who did not undergo transplant either died of their diseases before transplant or remained in remission with marrow reserved for possible future treatment if recurrent disease were to ensue. Early in the study two patients experienced disabling cerebellar toxicity and mucositis when a single daily dose of 5-FU exceeded 30 mg/kg intravenously (IV). Thereafter, most patients received a dose of 15 mg/kg IV daily for 3 days (Table 1 ) and the time interval between initial 5-FU injection and date of marrow harvest (5-FU time interval or FTI) was varied. All patients gave informed consent before 5-FU treatment, marrow harvest, and transplant according to University of Virginia Human Investigational Review Board guidelines.
Patients were taken to the operating room where under a general anesthetic, multiple aspirations of marrow were obtained from the posterior and anterior iliac crests using syringes prepared with McCoy's medium (GIBCO BRL, Grand Island, NY) and
preservative-free heparin. The marrow was pooled in I-L metal beakers or Fenwal marrow collection units that contained 10,000 to 15,000 U of heparin (Organon, Inc, W. Orange, NJ) and 100 to 150 mL of McCoy's medium.
The total volume of BM, McCoy's medium, and preservative-free heparin were recorded and cell counts were performed. Cells were layered in 30-to 40-mL aliquots over approximately 15 mL Lymphocyte Separating Media (Organon Teknika Corp, Durham, NC) and spun at 1,450 rpm for 30 minutes. Cells were collected at the interface and washed twice with Hanks', pooled, and resuspended in diluting medium at a concentration of 60 X IO6 nucleated cells/mL. A solution containing 10% dimethyl sulfoxide (DMSO) plus 20% AB0 Rh-compatible donor serum in McCoy's was added in equal amounts to the cell suspension that was kept on ice. The vials containing the mixture were placed in a CryoMed Control Rate Freezer (Marietta, OH) and were cooled at a rate of -1 "C/minute until a temperature of -3OOC was reached. At that time, the freezing rate was increased to IO"C/minute until the tem-
Marrow cryopreservation.
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At the time of marrow infusion cells were thawed rapidly in a 37°C waterbath and diluted with 2% donor serum and McCoy's to a concentration of 5.0 X IO6 cells/mL. The suspension was placed in a Fenwal bag (Baxter, Deerfield, IL) and infused into the patient over 2 to 6 hours.
Marrow transplant conditioning regimen and supportive measures. The CBV regimen was modeled after the regimen described by Jagannath et alZ0 and consisted of cyclophosphamide 1.5 g/m2 IV per day, days -6 through -3; BCNU 300 mg/m2 IV, day -6; and etoposide 300 mg/m2 IV per day, days -6 through -3; and marrow was infused on day 0. Red blood cell (RBC) transfusions were administered to maintain patient hematocrits above 25 and platelet transfusions were administered to maintain platelet counts at or above 20,000/mm3. All blood products received 1,500 cGy of radiation.
Double-layer agar cultures were prepared in 35-mm Petri dishes (Falcon; Fisher, Springfield, NJ). Alpha medium containing 20% preselected fetal calf serum (FCS) was used for all cultures. Cultures were plated in duplicate or triplicate at a density of IO5 cells/dish in the overlay. Incubations were performed for 14 and 28 days at 37°C in an atmosphere containing 5% 02, 10% C02, and 85% N2.
Colonies over 50 cells were scored using a dissecting microscope at 2X magnification. HPP colonies were scored as dense colonies greater than 0.5 mm in diameter. Colony morphology was determined on formalin-fixed whole agar slide preparations. Slide preparations were stained with hematoxylin and examined under a microscope.
The cytokines used for the in vitro clonal assays and the final concentration of cytokine in the assays (in parentheses) are as follows:
purified recombinant human G-CSF (6,250 U/mL), GM-CSF (39 1 U/mL), 1L-3 (44 ng/mL), and IL-6 (62.5 ng/mL) from Amgen (Thousand Oaks, CA); rhIL-6 (62.5 ng/mL) supplied by Immunex Corp (Seattle, WA); rhIL-1 (3,125 U/mL) supplied by Biogen (Boston, MA); and human IL-3 (44 ng/mL) and rhCSF-1 (625 U/mL) supplied by Genetics Institute (Cambridge, MA). Light-density cells on BM samples were incubated with high-specific activity 3H thymidine (20 Ci/mmol; New England Nuclear, Boston, MA) for 20 minutes, then washed in excess cold thymidine. Cells were plated as described above. Cells incubated with an equimolar amount of nontritiated thymidine were plated as controls; a mixture of cells incubated with hot and cold thymidine were also plated as a control. Results were expressed as percent kill; the ratio of colonies grown after 'H thymidine exposure to cells incubated with cold thymidine?' Hematopoietic recovery parameters from I5
5-FU-pretreated/CBV-conditioned/transplanted patients were compared with 17 patients receiving CBV who did not receive 5-FU before marrow harvesting (historical controls). Hematologic recovery was measured by determining the number of days to resolution of neutropenia (to > 100/mm3, r500/mm3, > l,OOO/mm', > 1 ,500/mm3) and thrombocytopenia (to >50,000/mm3, > 100,W/mm3, unrelated to transfusions). For platelet counts the day of recovery was recorded if a particular value was equaled or exceeded on 2 consecutive days without platelet transfusions. Most patients who were discharged before complete hematologic recovery had counts measured as outpatients 2 to 3 times per week until recovery exceeded 1,500/mm3 neutrophils and IOO,OOO/mm' platelets. Probability of recovery to each level was calculated using Kaplan-Meier survival analysis and significance was determined using the logrank method of MantelHaenszel. Median and mean time to recovery were compared between each group using chi-squared statistic^.^^^^^ An attempt was made to compare the degree of prior therapy preharvest between the two groups Clonogenic assays.
Tritiated thymidine suicide.

Statistical analysis.
by assessing the number of previous chemotherapy treatment repimens to which each patient was exposed. A course of prior radiation therapy counted as a treatment regimen and was included in the total number of treatments (Table I) . No attempt was made to quantify number of courses of chemotherapy administered within a particular regimen. The dose of 5-FU administered or the FTI were correlated with numbers of progenitor cells generated in vitro using scatter-plot diagrams. Correlation coefficients were generated for each progenitor cell assay value and dose or FTI. Also, using scatter-plot diagrams the dose or FTI was analyzed in relation to hematologic recovery. (Table 2) . Similarly, the volume per kilogram of marrow procured at harvest was substantially diminished in the 5-FU-treated group ( Table 2) .
RESULTS
Nucleated cell counts/marrow volumes.
Enrichment of progenitor cells. In general, marrow "priming" with 5-FU enhanced the number of progenitor cells determined by clonogenic assays. 5-FU pretreatment augmented the number of CFU-C. Individually, the combination of GM-CSF and 1L-3 increased the total number of colonies in 8 of 10 patients shown (Fig IA) . In a series of 20 patients, total CFU-C are augmented by 5-FU pretreatment in response to a wide array of growth factors (Fig 1B) . A significant increase was not observed when marrow was stimulated with G-CSF alone (Fig 1B) . HPP-CFC were found infrequently in normal marrow (Fig  2) . The mean number of HPP-CFC observed per 100,000 cells plated is shown after incubation for 14 and 28 days. Optimal growth was seen in response to the combination of GM-CSF and IL-3 after incubation for 28 days. The mean number of HPP-CFC coloniesgenerated was 0.8 per 100,000 cells plated. HPP-CFC were observed in low frequency from marrow pretreated with 5-FU at 14 days of incubation ( Figs  3A and 4) . At 28 days the generation of greater numbers of HPP was noted (Fig 3B) . GM-CSF and IL-3 interacted synergistically to yield approximately 3.2 HPP per 100,000 cells plated. In four patients, stimulation of post-5-FU marrow with multifactor combinations (GM-CSF + IL-3; GM-CSF IL-I + IL-6 + CSF-1 + G-CSF) failed to affect total day 28 CFU-C colony growth. While the total number of colonies 
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POSt5-FU generated is not different, there is a striking difference in gross morphology. Multifactor combinations yielded heavy cellular backgrounds with loose colonies up to several millimeters in diameter. GM-CSF and IL-3 produced many high, "classic" HPP, but morphology in all colonies was mixed with granulocytes and macrophages and occasionally large cells that appeared to be megakaryocytes.
After toxicity was noted at higher doses of 5-FU, a dosage of 15 mg/kg IV daily for 3 days was established while the time interval between 5-FU administration and marrow harvest (FTI) was varied. Scatter plots showed enhanced CFU-C and HPP-CFC at 14 days of culture when FTI equaled 14 to 18 days. Enrichment of HPP-CFC at 28 days of culture was noted when FTI equaled 10 days (not shown). Correlation coefficients did not establish any linear relationships between FTI and progenitor cell number.
Thymidine suicide data from three patients show that the number of cells in cycle ranged from 17% to 42% depending on the system used. The number of HPP-CFC in these experiments was too low to permit analysis of this aspect.
Thymidine suicide. Hematopoietic recovery posttransplant. All patients were evaluable for PB count recovery after transplantation. No patients died of complications related to BMT. The mean number of treatment regimens to which patients were exposed preharvest (including radiation therapy and chemotherapy)
were comparable between the two groups (2.41 v 2.40, P = Hematologic recovery parameters for each group are summarized in Tables 1 and 3 and Fig 5. Based on probability of recovery, these results show improved platelet recovery time to levels of 50,000/mm3 or 100,000/mm3 in patients receiving post-FU marrow compared with a similar group of patients treated without 5-FU priming. Median recovery times to each of the neutrophil or platelet levels according to each group are shown in Table 3 . Similarly, we compared the recovery times within the largest group of patients with a common diagnosis (lymphoma) and found that the difference in platelet recovery continued to favor the 5-FU-treated group. Median times to recovery comparing I3 patients with lymphoma in the untreated group with 11 patients with lymphoma in the 5-FU-treated group show recoveries to 50,000/ mm3 of 33 and 20 days, respectively ( P = .0062), and recoveries to 100,000/mm3 of 40 and 33 days, respectively (P = ,0049).
Based on the analysis of patients pretreated with 5-FU, no particular dose or schedule of 5-FU administration correlated with improved hematologic recovery.
.97).
DISCUSSION
Extensive studies in murine systems have characterized several classes of hematopoietic progenitor cells important for marrow repopulation. Till and M c C~l l o c h~~ described the colony forming unit spleen (CFU-S); later work by Hodgson and Bradley16 recognized the day 14 CRJ-S as a primitive cell capable of producing multilineage colonies in the spleen of irradiated mice. Bradley et all8 have studied another progenitor in murine systems, termed the HPP-CFC, which can give rise to large (>0.5 mm) dense macrophage colonies in In these experiments the generation of HPP-CFC and the enhancement of marrow recovery are consistent with those obtained in the murine system. In previous reports we have described a human HPP-CFC with properties similar to the murine ce11.26-28 Our results confirm and extend these initial observations that human HPP-CFC occurs with greater frequency in 5-FU-primed marrow compared with either normal marrow or pre-FLJ patient marrow, but also indicates that only 80% of post-FU marrow show increased concentration of HPP-CFC. It is possible that 5-FU eliminates mature, nonproliferating cells from the BM, concentrating or artifactually increasing the number of progenitor cells plated.
Although the post-FU marrow cellularities and volumes obtained at harvest were substantially diminished by approximately one-third compared with unmanipulated marrow, this could not account for the degree of HPP-CFC or colonyforming unit-granulocyte macrophage (CFU-GM) enrichment, which was often fourfold to sixfold greater. The generation of HPP-CFC appeared to be enhanced by the addition of at least two hematopoietic growth factors. Cells from these patients were responsive to combinations of growth factors such as GM-CSF and IL-3 or, to a lesser extent, G-CSF and GM-CSF, and grew over relatively long periods in culture. Multifactor combinations showed synergistic effects with GM-CSF and IL-3, but no further improvement with the addition of up to six factors. In these serum-replete systems, inhibitors or subliminal concentrations of growth factors may have limited the response to six-factor combinations. The use of serum-free culture systems may provide more accurate information about multifactor responsive HPP-CFC. 27 Patients who received 5-FU-"primed" marrow displayed normal neutrophil recovery post-ABMT, and marginal improvement in neutrophil recovery to 1,500/mm3 was noted in the 5-FU-treated group. The "post-5FU" patients showed a more rapid platelet recovery post-ABMT as compared with those patients who received autologous marrow harvested without 5-FU priming. Uncontrolled differences in the patient populations do not seem to explain the more rapid platelet recovery observed in the 5-FU-treated group. Both 5-FU-treated and control groups were comparable in terms of diagnosis, marrow cellularity, lack of prior pelvic irradiation, marrow transplant conditioning regimen, extent of previous radiotherapy, and chemotherapy. Although the magnitude of preceding therapy is difficult to standardize for a heterogeneous patient population, we approximated the amount of therapy administered by calculating the number of prior treatment regimens, including radiation therapy to which the patient was exposed. The mean number of treatment regimens administered per patient in each group was comparable.
Based on the in vivo hematologic recovery data, the optimum dosage or schedule for 5-FU administration was not apparent from these studies. Initially, after the development of cerebellar toxicity and significant mucositis in two patients who received dosages greater than 30 mg/kg/d, we did not escalate dosages above what would be considered standard for 5-FU. In the murine model Bradley et all8 administered 150 mg/kg of 5-FU by intraperitoneal injection; however, comparable doses extrapolated to humans would be substantially less.
The findings in these studies have several implications. First, it may be possible to devise strategies to further enhance HPP-CFC generation and improve marrow recovery posttransplant. The use of 5-FU in other schedules or alternatively, other agents, may prove beneficial. Second, a number of animal studies have used 5-FU to cycle progenitor or stem cells in order to enhance retroviral gene transfer. Our studies suggest that 5-FU administered to humans before marrow harvest also may cycle progenitor cells or enrich for progenitor cells. Whether post-5-FU marrow will be an appropriate vehicle for gene transfer awaits further study, but the present data indicate that post-5-FU marrow can be used safely in autologous marrow transplant without adverse effect on recovery and with a positive effect on immediate platelet renewal. These data have to be balanced against murine studies indicating that post-5-FU marrow may show defective engraftment when infused into normal non-myelosuppressed mice."
In summary, we have shown increased generation of HPP-CFC in patients treated with 5-FU. Administration of 5-FU in these dosages appeared to be safe because marrow from these patients led to normal hematopoietic reconstitution after ABMT and improved platelet recovery.
